New EU regulations on health technology assessments (HTAs) could be a double-edged sword, said speakers from industry at the Cell and Gene Meeting on the Med on April 20-22. While the new rules could solve some of the challenges in assessing advanced therapies, including a lack of data at launch, they could also lead to added burden for companies.
Speakers at the event organized by the Alliance for Regenerative Medicine (ARM), which represents companies developing advanced therapy medicinal products (ATMPs), also revealed that pay-for-performance deals had been key to...